



International Society of Hypertension
Science to Science Member Meeting
Monday, February 20, 2023

Meeting Time:

US CST Time	US EST Time	London /GMT	Munich / Paris	AUS Perth	AUS Melbourne
8:00 am	9:00 am	2:00 pm	3:00 pm	10:00 pm	1:00 am

Date/Time: Virtual Zoom Meeting – 2 hours

Meeting Purpose to Discuss:

- Renal denervation including the latest insights on the science of renal denervation
- Most recent Global Renal Denervation Clinical Data and understanding behind it
- Thinking around Hypertension treatment pathway considering introduction of renal denervation to appropriate patients.

Desired Outcomes:

- To have a better understanding on up-to-date clinical evidence on renal denervation
- To share the latest thinking on pathway implementation and patient selection
- To gain an understanding where gaps may exist

Science to Science Agenda (2 hours):

Time – London	Topic	Moderators / Speakers
2:00 – 2:10 PM	Welcome, Opening Comments and Introduction <ul style="list-style-type: none"> • ISH Co-Chair / Moderators 	Professor Bryan Williams Professor George Stergiou Professor Markus Schlaich
2:10 – 2:20 PM	Science Revisited <ul style="list-style-type: none"> • Latest insights on the science of renal denervation 	Doug Hettrick, PhD
2:20 – 2:50 PM	Clinical Data <ul style="list-style-type: none"> • To discuss the most recent Global Renal Denervation Clinical data published and understand: <ul style="list-style-type: none"> ○ Impressions of the Clinical Data and Outcomes ○ Impact of the Clinical Data ○ How safety is assessed ○ Impression about BP reduction from technology (device) versus medications ○ How durable is the response ○ How co-morbidities (diabetes, obesity, etc.) fare with Renal Denervation 	Jeffrey Popma, MD
2:50 – 3:15 PM	Critical Appraisal Discussion <ul style="list-style-type: none"> • Observations, insights, clarifying questions, viewpoints related to the renal denervation clinical data 	Moderated by: Professor Markus Schlaich Professor George Stergiou
3:15 – 3:35 PM	Patient Selection <ul style="list-style-type: none"> • To understand: <ul style="list-style-type: none"> ○ Insights on how Health Care Professionals globally are thinking about HTN Treatment Pathway considering introduction of renal denervation 	Doug Hettrick, PhD

	○ Non-adherence issues in blood pressure treatment	
3:35 – 4:00 PM	Critical Appraisal Discussion <ul style="list-style-type: none"> • Observations, insights, clarifying questions related to patient selection 	Moderated by: Professor Bryan Williams Professor George Stergiou
4:00 PM	Meeting Adjourn	Professor Bryan Williams Professor George Stergiou Professor Markus Schlaich

Meeting Attendees

ISH Members:

- ISH Council Members / Regional Leads
- Non-Invasive Cardiologists; Nephrologists; HTN Specialists, Renal Specialists; Proceduralists
- MDs, FASN, FAHA, FACP, FACC
- Directors of HTN / Internal Medicine / Nephrology Departments / CMO / Chief of Dept.
- Professors of Medicine (Div. of Cardiology, Internal Medicine)

ISH Chairs and Moderators:

Professor Bryan Williams, University College London – Co-Chair (ISH President 2022-2024)
Professor George Stergiou, University of Athens – Co-Chair (ISH Secretary 2022-2024)
Professor Markus Schlaich, The University of Western Australia, Perth – Co-Chair

Medtronic Speakers and Attendees:

Jeffrey Popma, MD	Vice President and Chief Medical Officer
Doug Hettrick, PhD	Sr. Program Director, Clinical Research and Medical Science
Jason Fontana, PhD	VP CRDN Strategy and Marketing Leader, VP Coronary Marketing
Gabe Lazarus	Sr. Director, Renal Denervation Global Market Access
Yousuf Dalal	Director, Renal Denervation Global Clinical
Kris Flanagan	Principal Global Market Development Manager